SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is attracting significant market attention and community speculation following reports of unsolicited takeover interest from rivals, particularly after its stock's recent slump and ahead of a leadership change. Discussion centers on potential acquisition prices and the company's perceived undervaluation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is surging following robust Q4 revenue growth driven by its ANKTIVA immunotherapy, fueling widespread community discussion about a potential short squeeze and significant global expansion for its cancer treatments.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike faces intense selling pressure amidst broader cybersecurity sector concerns, driven by market fears that new AI tools, like Anthropic's offering, threaten traditional security platforms. However, many in the community contend that these fears are overblown, asserting that AI will enhance, not replace, CrowdStrike's established AI-native endpoint and cloud protection.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its recent FDA approval of BYSANTI, a new chemical entity with patent protection extending to 2044, for treating bipolar I disorder and schizophrenia. The community is actively discussing the company's significant undervaluation compared to prior rejected acquisition offers, anticipating a substantial re-rating and potential further upside driven by its robust pipeline and the long-term revenue potential of its approved drugs.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as recent layoffs and a persistent decline to new all-time lows intensify bearish sentiment with its upcoming Q4 earnings report in focus, triggering widespread calls to fire management and heightening fears of further dilution among the community.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending due to a "SaaS-pocalypse" narrative, as fears that Anthropic's Claude AI tools will disrupt enterprise software are fueling aggressive selling. The community is debating whether this downturn is an overblown panic or a fundamental shift, with many calling current valuations irrational and the sector extremely oversold amidst record volume.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing a notable downturn, primarily driven by community reactions to renewed tariff uncertainty and escalating geopolitical concerns, sparking intense debate among traders regarding the possibility of a "V-shaped" recovery versus a deeper market "flush."

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point due to a prominent lawsuit alleging political debanking, alongside recent regulatory fines that fuel broader community discussions around the financial sector's stability and market integrity.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing significant market reaction after its next-generation obesity drug, CagriSema, demonstrated slightly less weight loss than Eli Lilly's Zepbound in a pivotal trial, failing to meet its primary endpoint. While this is driving a sharp sell-off and competitive concerns, many in the community highlight the strong uptake and superior efficacy of Novo's oral Wegovy pill, leading to strong dip-buying interest on perceived overreaction.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is driving intense debate ahead of its upcoming Q4 earnings, as investors are sharply divided between those aggressively buying the stock as deeply undervalued amidst AI disruption fears and those remaining bearish, citing continued analyst downgrades across the software sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: FibroGen (NASDAQ:FGEN) CEO Acquires 2,700 Shares of Stock

FibroGen, Inc (NASDAQ:FGEN - Get Free Report) CEO Thane Wettig bought 2,700 shares of the stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $9.10 per...

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of +59.85% and -34.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-approval-sale-fibrogen-china-astrazeneca">said</a>. &nbsp;The closing of the transaction remains subject to other contractual closing conditions and deliverables, the biopharmaceutical company added. The firm had previously expected the transaction to close by mid-2025. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FGEN">FGEN</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.The company said earlier this year that it would repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value following the closing of its transaction in a bid to simplify its capital structure. The transaction is further expected to extend the company’s cash runway into 2027, it added.Upon closing, AstraZeneca will obtain all rights to Roxadustat in China. Roxadustat is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients, irrespective of whether they are on dialysis.The company is currently considering a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. Myelodysplastic syndromes (MDS) are a group of cancers where bone marrow doesn't produce enough healthy blood cells.FGEN stock is down by 28% this year but up by about 1% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mission Bay headquarters and sign for FibroGen, a biotechnology company producing recombinant gelatins for medical devices and pharmaceuticals, San Francisco, California, 2016. (Photo by Smith Collection/Gado/Getty Images).

Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.

Equity

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.


FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

FGEN
FibroGen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FGEN News

FGENFibroGen Inc